Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARAMOUNT: Maintenance Pemetrexed in Advanced Non-Squamous NSCLC
NCT00789373Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2008
- Primary completion
- Jun 2010
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) comparing Maintenance Pemetrexed with Placebo (2 arms). Primary endpoint: Investigator-assessed Objective Progression-free Survival up to 19.3 months. Started Nov 2008; status: completed.
02
Drugs
pemetrexed
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00789373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00789373.